Artrite reumatóide e doença cardiovascular na atualidade: o que sabemos sobre essa associação e o que podemos fazer pelo paciente?

The interest in auto-immune diseases has been grown, mainly about cardiovascular illnesses. Rheumatoid arthritis has been considered an independent risk factor for coronary arterial disease in last years. Recently, different studies have been performed in order to better clarify crucial points in risk stratification and correct treatment for patients with rheumatoid arthritis. New specific therapies have been studying and promising reduction of cardiovascular risk. Thereby, we made a bibliographic revision to show the importance of atherosclerotic and inflammatory mechanisms in coronary artery disease. Furthermore, we suggested different strategies to establish risk stratification and treatment of cardiovascular diseases in patients with rheumatoid arthritis.O interesse em doenças auto-imunes vem crescendo a cada ano, principalmente sobre sua relação com doenças cardiovasculares.Especificamente a artrite reumatóide vem sendo considerada um fator de risco independente para doença arterial coronária nos últimos anos. Diversos estudos foram realizados recentemente com o objetivo de esclarecer pontos cruciais na estratificação de risco desses pacientes e no seu respectivo tratamentomedicamentoso adequado. Novas terapias específicas da doença reumatóide ainda estão em estudo, e prometem reduzir o risco cardiovascular a longo prazo. Desse modo, realizamos uma revisão bibliográfica ampla, utilizando as principais bases de dados nacionais e internacionais, com o objetivo de salientar a importância de mecanismos ateroscleróticos e inflamatórios sobre a doença arterial coronária. Além disso, frente às atuais evidências, sugerimos estratégias de estratificação de risco e tratamento da doença arterial coronária em pacientes com artrite reumatóide

Clinical manifestations and diagnosis of arrhythmogenic right ventricular dysplasia in sexagenary patient

A displasia arritmogênica de ventrículo direito (DAVD) é uma das principais causas de morte súbita em indivíduos jovens. Suas manifestações e consequente diagnóstico costumam ser precoces ainda na adolescência ou no adulto jovem. Nesse contexto, o diagnóstico em doente sexagenário sem história familiar sugestiva ou sintomas prévios e com possibilidade de tratamento torna esse caso único na literatura.Arrhythmogenic right ventricular dysplasia is one of the major causes of death in younger patients and its manifestations and diagnosis used to be early. In this context, diagnosis in a sexagenary patient without famylial history or previous symptoms and with possibility of correct treatment make this case unique

Mortality reduction with use of oral beta-blockers in patients with acute coronary syndrome

OBJECTIVES: Recent studies have revealed a relationship between beta-blocker use and worse prognosis in acute coronary syndrome, mainly due to a higher incidence of cardiogenic shock. However, the relevance of this relationship in the reperfusion era is unknown. The aim of this study was to analyze the outcomes of patients with acute coronary syndrome that started oral beta-blockers within the first 24 hours of hospital admission (group I) compared to patients who did not use oral beta-blockers in this timeframe (group II). METHODS: This was an observational, retrospective and multicentric study with 2,553 patients (2,212 in group I and 341 in group II). Data regarding demographic characteristics, coronary treatment and medication use in the hospital were obtained. The primary endpoint was in-hospital all-cause mortality. The groups were compared by ANOVA and the chi-square test. Multivariate analysis was conducted by logistic regression and results were considered significant when

Manifestações clínicas e análise histopatológica pulmonar relacionadas a diferentes doenças em pacientes com tromboembolismo pulmonar fatal – um estudo em autópsias

Introdução: Tromboembolismo pulmonar (TEP) é uma das mais graves complicações dentre pacientes hospitalizados e permanece subdiagnosticado. Ainda hoje, sua fisiopatologia não está completamente elucidada. Objetivos: Correlacionar comorbidades, neoplasias, cirurgias e achados histológicos às manifestações clínicas associadas ao TEP. Métodos: Entre 2001 a 2008, foram revisadas 291 autópsias de pacientes cuja causa de morte foi TEP. Os seguintes dados foram obtidos: idade, sexo, manifestações clínicas, achados histológicos e principais doenças de base/comorbidades, neoplasias e cirurgias da última internação. Os achados histológicos foram categorizados em: dano alveolar difuso (DAD), edema agudo de pulmão (EAP), hemorragia intra-alveolar (HIA) e pneumonia intersticial linfo-plasmocítica (PILP). Odds ratios foram obtidas por regressão logística e foram consideradassignificativas quando p < 0,05. Resultados: A mediana de idade foi 64 anos. Cerca de 64% dos pacientes apresentava doenças cardiovasculares.O achado pulmonar mais prevalente foi EAP. Apenas 13% dos casos apresentaram suspeita clínica. Insuficiência respiratória esteve associada a EAP, HIA e DAD; assim como instabilidade hemodinâmica a HIA e DAD. Conclusões:Foram encontradas importantes associações entre achados clínicos e histológicos em pacientes com TEP. A compreensão dos mecanismos fisiopatológicos envolvidos com cada doença associada a TEP pode auxiliar no diagnóstico e no tratamento da doença.Introduction: Pulmonary thromboembolism (PTE) is one of the most fatal complications among hospitalized patients and remains undiagnosed. Its physiopathology and its epidemiology aren’t widely known in literature. Objectives: To correlate underlying diseases, different cancers and surgeries to histological findings and in-vivo manifestations associated to fatal PTE from autopsy reports. Methods: From 2,001 to 2,008, were reviewed 291 autopsies of patients whose cause of death was PTE. The following data were obtained: age, sex, clinical in-vivo manifestations, post-mortem pathological patterns and main associated underlying diseases, cancers and surgeries performed in last hospitalization. The pulmonary histopathological changes were categorized in: diffuse alveolar damage (DAD), pulmonary edema (PE), alveolar hemorrhage (AH) and lympho/plasmacytic interstitial pneumonia (LPIP). Odds ratios of positive relations were obtained by logistic regression and were considered significative when p < 0.05. Results: The median age was 64 years. 64% of patients presented cardiovascular illness associated to PTE. The most prevalent pulmonary finding was PE. Only 13% of cases had clinical suspect. Acute respiratory failure was positively related to PE, AH and DAD; as well hemodynamic instability to AH and DAD. Conclusions: We found important relations between clinical data and histological findings of fatal PTE patients. The understanding of pulmonary physiopathological mechanism involved with each PTE-associated disease can improve diagnosis in order to offer prompt treatment and reduce mortality

Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin

Background: In the setting of stable coronary artery disease (CAD), it is not known if the pleiotropic effects of cholesterol reduction differ between combined ezetimibe/simvastatin and high-dose simvastatin alone. Objective: We sought to compare the anti-inflammatory and antiplatelet effects of ezetimibe 10 mg/simvastatin 20 mg (E10/S20) with simvastatin 80 mg (S80). Methods and results: CAD patients (n = 83, 63 +/- 9 years, 57% men) receiving S20, were randomly allocated to receive E10/S20 or S80, for 6 weeks. Lipids, inflammatory markers (C-reactive protein, interleukin-6, monocyte chemoattractant protein-1, soluble CD40 ligand and oxidized LDL), and platelet aggregation (platelet function analyzer [PFA]-100) changes were determined. Baseline lipids, inflammatory markers and PFA-100 were similar between groups. After treatment, E10/S20 and S80 patients presented, respectively: (1) similar reduction in LDL-C (29 +/- 13% vs. 28 +/- 30%, p = 0.46), apo-B (18 +/- 17% vs. 22 +/- 15%, p = 0.22) and oxidized LDL (15 +/- 33% vs. 18 +/- 47%, p = 0.30); (2) no changes in inflammatory markers; and, (3) a higher increase of the PFA-100 with E10/S20 than with S80 (27 +/- 43% vs. 8 +/- 33%, p = 0.02). Conclusions: These data suggest that among stable CAD patients treated with S20, (1) both E10/S20 and S80 were equally effective in further reducing LDL-C; (2) neither treatment had any further significant anti-inflammatory effects; and (3) E10/S20 was more effective than S80 in inhibiting platelet aggregation. Thus, despite similar lipid lowering and doses 4x less of simvastatin, E10/S20 induced a greater platelet inhibitory effect than S80. (C) 2011 Elsevier Ireland Ltd. All rights reserved.Astra ZenecaAstraZenecaMerck/Schering PloughMerck/Schering PloughPfizerPfizerSao Paulo Research FoundationSao Paulo Research Foundation [FAPESP/05/57710-3